Nucleosides, nucleotides, and oligonucleotides modulate
diverse
cellular processes ranging from protein production to cell signaling.
It is therefore unsurprising that synthetic analogues of nucleosides
and their derivatives have emerged as a versatile class of drug molecules
for the treatment of a wide range of disease areas. Despite their
great therapeutic potential, the dense arrangements of functional
groups and stereogenic centers present in nucleic acid analogues pose
a considerable synthetic challenge, especially in the context of large-scale
manufacturing. Commonly employed synthetic methods rely on extensive
protecting group manipulations, which compromise step-economy and
result in high process mass intensities. Biocatalytic approaches have
the potential to address these limitations, enabling the development
of more streamlined, selective, and sustainable synthetic routes.
Here we review recent achievements in the biocatalytic manufacturing
of nucleosides and cyclic dinucleotides along with progress in developing
enzymatic strategies to produce oligonucleotide therapies. We also
highlight opportunities for innovations that are needed to facilitate
widespread adoption of these biocatalytic methods across the pharmaceutical
industry.